伴随性病理及其对利维体痴呆症的影响 - - 当前观点
1Institute of Clinical Neurobiology, 1150 Vienna, Austria.
International journal of molecular sciences
|August 28, 2025
概括
患有勒维体的痴呆症 (DLB) 通常与其他大脑疾病和障碍同时发生. 通过生物标志物识别这些并发症对于准确诊断和预测DLB进展至关重要.
科学领域:
- 神经学
- 神经科学
- 病理学
背景情况:
- 勒维体痴呆症 (DLB) 是一种主要的神经认知障碍,仅次于阿尔茨海默病 (AD).
- DLB经常表现出并发症,包括与阿尔茨海默病相关的神经病变 (ADNC),TDP-43蛋白病变以及心血管/衰老疾病.
- 脑血管病变和心血管疾病,如高血压和高脂血症是DLB的常见并发症.
研究的目的:
- 审查DLB中并发症的类型和频率.
- 评估这些并发症对DLB患者的临床影响.
- 评估生物标志物的有用性,以评估和预防DLB及其副病理.
主要方法:
- 对DLB并发症的神经病理学和临床研究的文献综述.
- 对DLB共存疾病的流行和影响进行分析.
- 对DLB诊断和进展预测的生物标志物的评估.
主要成果:
- 与阿尔茨海默病相关的神经病变 (ADNC) 和TDP-43蛋白病变是DLB的常见并发症.
- 大脑血管病变,特别是大脑粉样血管病变,是最常见的非神经退行性并发症.
- 心血管疾病,高血压和高脂血症在DLB患者中是非常常见的并发症.
结论:
- 同病症显著影响DLB的临床表现和进展.
- 对DLB的临床试验设计应纳入并发症的影响.
- 对共同病理的生物标志物评估可以提高诊断准确度,并预测DLB的临床结果.
更多相关视频
07:26Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
Published on: September 26, 2019
8.0K
12:28Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
17.5K
相关概念视频
Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
Parkinson's Disease: Overview
702
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
702
Dementia
165
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
165
Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
Parkinson's Disease: Treatment
376
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
376
Neural Regulation
39.9K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.9K
